233 related articles for article (PubMed ID: 35382853)
1. Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?
Postma MJ; Noone D; Rozenbaum MH; Carter JA; Botteman MF; Fenwick E; Garrison LP
Orphanet J Rare Dis; 2022 Apr; 17(1):157. PubMed ID: 35382853
[TBL] [Abstract][Full Text] [Related]
2. Pricing and reimbursement of orphan drugs: the need for more transparency.
Simoens S
Orphanet J Rare Dis; 2011 Jun; 6():42. PubMed ID: 21682893
[TBL] [Abstract][Full Text] [Related]
3. Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?
Hughes-Wilson W; Palma A; Schuurman A; Simoens S
Orphanet J Rare Dis; 2012 Sep; 7():74. PubMed ID: 23013790
[TBL] [Abstract][Full Text] [Related]
4. Reimbursed Price of Orphan Drugs: Current Strategies and Potential Improvements.
Mincarone P; Leo CG; Sabina S; Sarriá-Santamera A; Taruscio D; Serrano-Aguilar PG; Kanavos P
Public Health Genomics; 2017; 20(1):1-8. PubMed ID: 28359063
[TBL] [Abstract][Full Text] [Related]
5. International experiences in multicriteria decision analysis (MCDA) for evaluating orphan drugs: a scoping review.
Lasalvia P; Prieto-Pinto L; Moreno M; Castrillón J; Romano G; Garzón-Orjuela N; Rosselli D
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):409-420. PubMed ID: 31210065
[No Abstract] [Full Text] [Related]
6. Orphan drug policies and use in pediatric nephrology.
Karpman D; Höglund P
Pediatr Nephrol; 2017 Jan; 32(1):1-6. PubMed ID: 27738765
[TBL] [Abstract][Full Text] [Related]
7. Valuation of Treatments for Rare Diseases: A Systematic Literature Review of Societal Preference Studies.
Dabbous O; Chachoua L; Aballéa S; Sivignon M; Persson U; Petrou S; Richardson J; Simoens S; Toumi M
Adv Ther; 2023 Feb; 40(2):393-424. PubMed ID: 36451072
[TBL] [Abstract][Full Text] [Related]
8. Orphan drugs policies: a suitable case for treatment.
Drummond M; Towse A
Eur J Health Econ; 2014 May; 15(4):335-40. PubMed ID: 24435513
[TBL] [Abstract][Full Text] [Related]
9. Orphan drugs for rare diseases: is it time to revisit their special market access status?
Simoens S; Cassiman D; Dooms M; Picavet E
Drugs; 2012 Jul; 72(11):1437-43. PubMed ID: 22747423
[TBL] [Abstract][Full Text] [Related]
10. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
Danzon PM
Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
[TBL] [Abstract][Full Text] [Related]
11. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
12. A review of international coverage and pricing strategies for personalized medicine and orphan drugs.
Degtiar I
Health Policy; 2017 Dec; 121(12):1240-1248. PubMed ID: 29033060
[TBL] [Abstract][Full Text] [Related]
13. Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective.
Tafuri G; Bracco A; Grueger J
Expert Rev Pharmacoecon Outcomes Res; 2022 Apr; 22(3):381-389. PubMed ID: 34930086
[TBL] [Abstract][Full Text] [Related]
14. Cost Effectiveness of Monoclonal Antibody Therapy for Rare Diseases: A Systematic Review.
Park T; Griggs SK; Suh DC
BioDrugs; 2015 Aug; 29(4):259-74. PubMed ID: 26263903
[TBL] [Abstract][Full Text] [Related]
15. What is known about the cost-effectiveness of orphan drugs? Evidence from cost-utility analyses.
Picavet E; Cassiman D; Simoens S
J Clin Pharm Ther; 2015 Jun; 40(3):304-7. PubMed ID: 25891411
[TBL] [Abstract][Full Text] [Related]
16. Limits on use of health economic assessments for rare diseases.
Hyry HI; Stern AD; Cox TM; Roos JC
QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281
[TBL] [Abstract][Full Text] [Related]
17. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
Iskrov G; Miteva-Katrandzhieva T; Stefanov R
Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
[TBL] [Abstract][Full Text] [Related]
18. Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs.
Chambers JD; Silver MC; Berklein FC; Cohen JT; Neumann PJ
J Gen Intern Med; 2020 Sep; 35(9):2629-2636. PubMed ID: 32291711
[TBL] [Abstract][Full Text] [Related]
19. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
Rodriguez-Monguio R; Spargo T; Seoane-Vazquez E
Orphanet J Rare Dis; 2017 Jan; 12(1):1. PubMed ID: 28057032
[TBL] [Abstract][Full Text] [Related]
20. Orphan Drugs in Oncology.
Korchagina D; Jaroslawski S; Jadot G; Toumi M
Recent Results Cancer Res; 2019; 213():109-142. PubMed ID: 30543010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
